Navigation Links
Otonomy Files Registration Statement for Proposed Initial Public Offering
Date:7/14/2014

SAN DIEGO, July 14, 2014 /PRNewswire/ -- Otonomy, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. All shares of common stock to be sold in the offering will be offered by Otonomy. The number of shares to be offered and the price range for the proposed offering have not yet been determined.

J.P. Morgan Securities LLC and BofA Merrill Lynch are acting as joint book-running managers for the offering, and Piper Jaffray & Co. and Sanford C. Bernstein & Co., LLC are acting as co-managers for the offering.

A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus may be obtained from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204; or BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attention: Prospectus Department, or by email at: dg.prospectus_requests@baml.com.

Logo - http://photos.prnewswire.com/prnh/20130806/MM59802LOGO


'/>"/>
SOURCE Otonomy, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Otonomy Doses First Subjects in Phase 3 Clinical Trials of OTO-201 in Pediatric Patients Undergoing Ear Tube Placement Surgery
2. Otonomy Enrolls First Patient in Pivotal Phase 2b Study of OTO-104 in Menieres Disease
3. Otonomy Acquires Assets and Patent Rights for Tinnitus Program
4. Otonomy Completes $45.9 Million Series C Equity Financing
5. MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics
6. EntreMed Files New Drug Global Clinical Trial Application For ENMD-2076 With China CFDA
7. Flexion Therapeutics Files Registration Statement for Proposed Initial Public Offering
8. Ormco Corporation Files Appeal to the Federal Court Against Ortho Classic H4 Bracket Patent Infringement
9. Molecular Profiles Joins Leading Consortium To Drive Paediatric Formulation Development
10. Family Talk Files Lawsuit Challenging Obamas Abortion Pill Mandate
11. Polaris Group Files New IND for ADI-PEG 20 in Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... for their devotion to personalized service, SMP Pharmacy Solutions announces ... the South Florida Business Journal,s 50 Fastest-Growing Companies, and listed ... national specialty pharmacy has found its niche.  To that end, ... honored by SFBJ as the 2017 Power Leader in Health ... his award in October, Bardisa said of the three achievements, ...
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... , ... Many families have long-term insurance that covers care for a family ... for care if the client has a cognitive impairment diagnosis. , “What this ... often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, owner ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... advisory services for healthcare compliance program management, will showcase a range of technology ... Association for Assisted Living (NCAL) Convention and Expo to be held October 14–18, ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
Breaking Medicine News(10 mins):